Review Article

Chinese Herb and Formulas for Promoting Blood Circulation and Removing Blood Stasis and Antiplatelet Therapies

Yue Liu, Hui-Jun Yin, Da-zhuo Shi, and Ke-ji Chen

Cardiovascular Diseases Center, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China

Correspondence should be addressed to Hui-Jun Yin, huijunyin@yahoo.com.cn

Received 14 September 2011; Accepted 22 December 2011

Copyright © 2012 Yue Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Atherothrombosis, which directly threatens people's health and lives, is the main cause of morbidity and mortality all over the world. Platelets play a key role in the development of acute coronary syndromes (ACSs) and contribute to cardiovascular events. Oral antiplatelet drugs are a milestone in the therapy of cardiovascular atherothrombotic diseases. In recent years, many reports have shown the possibility that “resistance” to oral anti-platelet drugs and many adverse reactions, such as serious bleeding risk, which provides an impetus for developing new anti-platelet drugs possesses highly efficiency and fewer adverse effects. Study on the blood stasis syndrome and promoting blood circulation and removing blood stasis is the most active field of research of integration of traditional and western medicine in China. Blood-stasis syndrome and platelet activation have close relationship, many Chinese herb and formulas for promoting blood circulation and removing blood stasis possess definite anti-platelet effect. This paper covers the progress of anti-platelet mechanism of Chinese herb and formulas for promoting blood circulation and removing blood stasis and is to be deeply discussed in further research.

1. Introduction

Cardiovascular and cerebrovascular events have become the major killer of people's health and life all over the world. Rupture of atherosclerotic plaque in an artery wall and the ensuing thrombotic events are the triggers for acute ischemic injury. Activated platelets play a pivotal role in the formation of pathogenic thrombi underlying acute clinical manifestations of vascular atherothrombotic disease. Oral antiplatelet drugs are a milestone in the therapy of cardiovascular atherothrombotic diseases and provide the primary and secondary prevention strategy to combat these diseases. Efficient antiplatelet therapy can make the death rates of heart disease and stroke decline by about 25% [1, 2]. Commonly used oral antiplatelet drugs include cyclooxygenase inhibitor aspirin, the glycoprotein IIb/IIa inhibitor ReoPro, and the P_{2}Y_{12} inhibitor clopidogrel, et al. Many clinical studies show that dual antiplatelet therapy with aspirin and clopidogrel is currently the standard of drugs for prevention of adverse cardiovascular events in most patients at high risk owing to acute coronary syndromes or recent placement of a stent.

But along with prolonging of treatment by dual or triple antiplatelet drugs, the effectiveness and security have garnered particular attention in clinic. Despite their proven benefit, recurrent cardiovascular events still occur in those taking antiplatelet drugs. This has led to the concept of antiplatelet resistance [3], most commonly aspirin resistance as this drug is the cornerstone of most regimens. Although there are some debates on definition and mechanism of antiplatelet resistance [4, 5], it cannot be denied that it has important clinical significance. At the same time, numerous adverse reactions including serious bleeding risk (digestive and nervous systems) and combination with PPIs and statin [6, 7], which limit the clinical practice of antiplatelet drugs. So developed novel classes of antiplatelet agents possess high efficiency, and fewer adverse effects have been always the research focus for prevention of cardiovascular disease. Modern medicine and pharmacology has done a lot of valuable exploration, newer agents are in development recent years that include prasugrel, cangrelor, ticagrelor, and vorapaxar, et al. [8].

Study on the blood stasis syndrome (BSS) and promoting blood circulation and removing blood stasis (PCBRBS) is the most active field of research of integration of traditional and western medicine in China. During the past 50 years, much
significant progress has been made from theory, experiments to clinic fields based on the inherit, and innovation of thoughts in traditional Chinese medicine [9], to clarify the treatment regulations and principles of PBCRBS, which has already got consensus in medical community in China. A lot of formulas for PBCRBS (see Table 1) have showed great antiplatelet effect in clinic, and most of them are the Chinese patent drugs. On the prevention of atherosclerosis or vulnerable plaque, Chinese and Western medicine have the consensus that stabling plaque and promoting blood circulation is the main function of platelet and has key role in the physiological hemostasia and pathogenesis of atherothrombosis. Platelet activates when it adheres to breakage of vessel or has been induced by activator. Activated platelet membrane glycoprotein (GP) IIb/IIIa exposes its fibrinogen receptor with the participation of Ca^{2+}, one fibrinogen can bind to at least two GP IIb/IIIa at the same time, and the platelet clump together with fibrinogen by GP IIb/IIIa. The typical aggregation is induced by different activators, which included the following two aspects, one is chemical agents such as ADP, collagen, thrombin, AA, and PAF; the other is shear stress. It is now taken that platelet aggregation rate (PAR) is the evaluation criterion of the intensity. Born [16] designed the platelet aggregation analyzer in 1962 by the turbidimetry principle which to accelerate the understanding of thromboembolic diseases significantly. Active principles such as ferulic acid [23], ligustrazine [24], propyl gallate [25], resveratrol [26], cardione [27], Total flavone in Sanguis Dracoris [28], Salvianolic acid B [29], Hirulog [30], and Safflower flavin [31] et al. can inhibit the platelet aggregation induced by AA, ADP, PAF, collagen, and thrombin to some extent, bringing out the superior antiplatelet effect.

## 2. Antiplatelet Mechanism of Chinese Herb and Formulas of Promoting Blood Circulation and Removing Blood Stasis

### 2.1. Inhibition of Platelet Aggregation

Platelet aggregation means the clumping together of platelets in the blood, which is the main function of platelet and has key role in the physiological hemostasia and pathogenesis of atherothrombosis. Activated platelet membrane glycoprotein (GP) IIb/IIIa exposes its fibrinogen receptor with the participation of Ca^{2+}. The aggregation is induced by different activators, which included the following two aspects, one is chemical agents such as ADP, collagen, thrombin, AA, and PAF; the other is shear stress. It is now taken that platelet aggregation rate (PAR) is the evaluation criterion of the intensity. Born [16] designed the platelet aggregation analyzer in 1962 by the turbidimetry principle which to accelerate the understanding of platelet aggregation. Now PAR was considered as the marker of antiplatelet efficacy evaluation and was used intensively in medical research of platelet. Studies show that the vast majority of Chinese herb and formulas for PBCRBS such as Xiongshao Capsule [17], Compound Danshen dripping pills [18], Buyanghuanwu Decoction [19], Xuesaitong Capsule [20], Da Huang Zhe Chong pil [21], and Tongxinghuo Capsule [22] et al. can reduce the PAR of patients or animal model of thromboembolic diseases significantly. Active principles such as ferulic acid [23], ligustrazine [24], propyl gallate [25], resveratrol [26], cardione [27], Total flavone in Sanguis Dracoris [28], Salvianolic acid B [29], Hirulog [30], and Safflower flavin [31] et al. can inhibit the platelet aggregation induced by AA, ADP, PAF, collagen, and thrombin to some extent, bringing out the superior antiplatelet effect.

### Table 1: The ingredient of frequently used formulas for promoting blood circulation and removing blood stasis.

| Names of formulas          | Ingredients of formulas                                           | Label                        |
|---------------------------|-------------------------------------------------------------------|------------------------------|
| Xiongshao capsule         | Szechuan Lovage Rhizome, Red Paeony Root                          | Chinese patent drug          |
| Compound danshen dripping pills | The root of red-rooted salvia, Panax notoginseng, Borneol         | Chinese patent drug          |
| Buyanghuanwu decoction    | Radix Astragali Bunge, Peach Seed, Safflower, Szechuan Lovage Rhizome, Angelica sinensis, Red Paeony Root, earthworm | Chinese patent drug          |
| Xuesaitong capsule        | Panax Notoginsenosides                                           | Chinese patent drug          |
| Tongxinluo capsule        | Sanguisauge, Scorpion, centipede, ground beettle, cicada slough, et al. | Chinese patent drug          |
| Danhong injection         | The root of red-rooted salvia, safflower                          | Chinese patent drug          |
| Taohongsiwu decoction     | Peach Seed, Safflower, Szechuan Lovage Rhizome, Angelica sinensis, white paeony root, Radix Rehmanniae Praeparata | Chinese patent drug          |
| Xue Fu Zhu Yu decoction   | Rhizome, Angelica sinensis, white paeony root, Radix Rehmanniae Praeparata, radix bupleuri, Platycodon grandiflorum, et al. | Chinese patent drug          |

### References

[10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31]
2.2. Inhibition of Platelet Release Reaction. Platelet release reaction means that many substances stored in α-granules, dense granule, and lysosome in platelet are released out of platelet upon different activator. These substances including CD62p (P-selection), GPIIb/IIIa compound, PKC, β-TG, PF-4, and Ca$^{2+}$, which has been considered as the usual evaluation indicator of screening the effective antiplatelet drug from Chinese herb and formulas for PBCRBS.

2.2.1. CD62P. CD62p (P-selection) is a 140 kD glycoprotein which is present in the granules of platelets and translocates rapidly to the cell surface after platelet activation and is generally considered to be the gold marker of platelet activation [32, 33]. Clinical research indicates that the expression of CD62p increases markedly in the different types of cardiovascular patients (including patients with stable angina and ACS) [34–36] and has found high positive correlation between CD62p level and blood stasis syndrome (BSS) [37]. So making the increased expression of CD62p after platelet activation dropped is taken for the one of the antiplatelet mechanisms and scientific measurements of Chinese herb and formulas for PBCRBS. According to the current studies, Danhong injection [38], Ligustrazine injection [39], Compound Danshen dripping pills [40], Taohongsiwu Decoction [41], and Tongxinluo capsule [42] can reduce the CD62p expression after platelet activation significantly and inhibit platelet activation in vivo, to show satisfactory effect of antiplatelet.

2.2.2. GPIIb/IIIa Compound. The detection of PAC-1 is considered as the sensitive and important marker of platelet activation [43], PAC-1 is the specific monoclonal IgMK, which only binds to activating platelet GPIIb/IIIa compound, while it has no recognition capability for resting one. The activation of GPIIb/IIIa depends on the platelet activation which makes the former change its configuration to have strong affinity with receptors. Using the flow cytometry to detect PAC-1 which has the characteristic of specific fast sensitive, and has splendid future in the study on screening antiplatelet drugs from Chinese herb and formulas for PBCRBS.

Da Huang Zhe Chong pill is the earliest formula of PBCRBS and is widely used for atherothrombotic disease treatment. Research shows that it has better antiplatelet aggregation ability than aspirin [44], the further study indicates that it can reduce the level of PAC-1 after ADP-induced platelet activation and of patients with coronary heart disease and cerebral infarction in clinic, which also has superior antiplatelet activation than aspirin [21] and is an ideal antithrombotic drug. Other study [45] found that Xue Fu Zhu Yu decoction can inhibit the ADP-induced expression of GPIIb/IIIa compound significantly and restrain the ADP-induced platelet activation, which provides experimental evidence to long-term treatment of coronary heart disease, and no symptoms of myocardial ischemia, et al.

2.2.3. PKC. protein kinase C (PKC), a ubiquitous protein kinase found in a variety of animal tissues, has been implicated in the regulation of many cellular processes and plays a central role in signal transduction. In platelets, the PKC is an important signaling mediator required for activation, secretion of granule contents, and aggregation [46]. During the process of platelet activation, close relationship between translocation of PKC in platelet and platelet function has been found. PKC has both cytosolic and plasma membrane-bound forms, and the former is the most abundant under resting conditions. The cytosolic form can translocate to the plasma membrane upon cell stimulation and elevation of cellular Ca$^{2+}$, one particular and important aspect of PKC activation is the intracellular redistribution of the enzyme from the cytosol to the cell membrane [44]. Now translocation or redistribution of PKC from the cytosolic form to the plasma membrane can be taken for an indicator of PKC activation [47].

Resveratrol (RESV), a well-known polyphenolic compound of, was extracted from Polygonum Cuspidatum, which was a Chinese herb for PBCRBS and has been efficaciously used in traditional Chinese medicine to treat several diseases, including thromboembolic diseases for over hundreds of years. In recent years, pharmacological studies have found that RESV possesses multifaceted cardiovascular benefits, but the mechanism is not clear. Recent research [48] shows that PKC distributed mostly across the cytosol of platelets in resting platelets and redistributed to the membrane later to be activated by ADP. If pretreated by RESV, PKC translocation to the membrane was partially inhibited in the platelets activated by ADP. These results suggested that RESV inhibited the PKC-mediated signal transduction pathway in platelets, and it might act as an inhibitor on PKC activity in platelets and serve as a novel antithrombotic agent.

2.2.4. PF-4 and β-TG. It is thought that PF-4 and β-TG are the specific indicators of platelet release reaction [49]. Both increases of PF-4 and β-TG indicate the height of platelet release reaction, which is common in thromboembolic disease and prethrombotic state. On the contrary, both decreases of PF-4 and β-TG indicate the suppression of platelet release reaction. β-TG can make the PGI$_2$ concentration and adenylate cyclase activity reduction, and then make cAMP decrease which bring about weak inhibition and enhance the aggregation of platelet [50, 51]. PF-4 can reduce the anticoagulation of heparan sulphate in endothelial cell and enhance the metabolism of membrane phospholipid and AA, to produce TXA$_2$, also PF-4 can promote precipitation and polymerization of fibrin monomer and accelerate platelet aggregation [52]. Research has found that Salvia miltiorrhiza Bunge injection [53] can reduce the PF-4 and β-TG concentration markedly to inhibit platelet aggregation.

2.2.5. Ca$^{2+}$. Calcium ion plays a vital role in the development of platelet activation. The transformation, aggregation, and release reaction of platelet are triggered by the increase of free calcium ion concentration of platelet [(Ca$^{2+}$)$_i$], which is the essential mechanism of thrombosis [54]. Studies have found that the increase of [Ca$^{2+}$)$_i$ in patient with CHD, meanwhile calcium antagonist can reduce [Ca$^{2+}$]$_i$ of platelet accompanied by inhibiting platelet aggregation [55].
TXA2 and PGI2 are the metabolites of AA, which are produced from 5-LOX and 12-LOX, respectively. TXA2 is a powerful vasoconstrictor and is involved in platelet aggregation, whereas PGI2 is a vasodilator and has antiplatelet properties.

**2.3. Influence of the Metabolic System of Arachidonic Acid**

The metabolic system of AA is important in the regulation of platelet function. TXA2 and PGI2 are produced through the metabolism of AA, and their balance is crucial for maintaining normal platelet behavior. TXA2 promotes platelet aggregation, whereas PGI2 inhibits it. The ratio of TXA2 to PGI2 is important in the regulation of platelet aggregation and thrombosis.

**2.3.1. Influence of the Metabolic System of Arachidonic Acid (AA)**

TXA2 and PGI2 are the metabolites of AA, which have the strong bioactivity of PG, and have a short half-life, quickly degraded to the TXB2 and 6-keto-PGF1α (6-keto-PGF1α), which means that TXA2 is a powerful vasoconstrictor and is involved in platelet aggregation, whereas PGI2 is a vasodilator and has antiplatelet properties. The balance of TXA2 and PGI2 is crucial for maintaining normal platelet behavior.

**2.3.2. Influence of the Metabolic System of cAMP and cGMP**

cAMP and cGMP in platelet are the second messengers of signal transmission, which make the different platelet activators acting on the specific receptor. The effect of cAMP and cGMP on platelet aggregation and activation is related to the phosphorylation of myoglobin. Studies [56, 57, 58] have indicated that some Chinese herbs, such as Salvia Miltiorrhiza, Ligusticum wallichii Franch, Carthamus tinctorius, Radix Paeoniae Rubra, and some active constituents as Ligustrazine, have the certain effect of calcium channel antagonists and have good results of inhibit platelet aggregation and activation. Another research [57] shows that Safflor yellow (a kind of soluble natural pigment of Carthamus tinctorius) can inhibit platelet release of 5-HT and Ca2+, which has similar effect to Ginkgolides (admitted PAF receptor antagonist), which means that Safflor yellow might suppress the platelet activation via inhibition of PAF and calcium influx.

**2.4. Influence of the Signal Transduction in Platelet.**

There is a series of signal transductions in platelet, which has close relationship with platelet activation. Upon agonist stimulation, specific receptor of membrane binds to the ligand to make the conformational changes and to activate the key enzymes action, which produces or releases the signal molecules and led to adhesion, aggregation, and reaction release to form thrombus at last. The mechanism of transmembrane signal transduction in platelet is unclear owing to more than one receptor bound by platelet agonist and the activated platelet release α-granules as secondary agonist to bring about amplification effect [69]. Platelet signal transduction pathway usually includes several aspects [70]: PI3-K pathway, PLC-β pathway, PTK pathway, MARK pathway, cAMP-PKA pathway, and PLA2 pathway. At present, most researches are about Phosphoinositide 3-kinase (PI3K). PI3K is a critical transmitter of intracellular signaling during platelet activation. The PI3K family is divided into three classes (I, II, and III). Depending on differences in the heterodimerization of catalytic subunits and regulatory subunits, class I is further divided into class Iα and class Iβ. Class Iα is involved in the regulation of platelet aggregation and activation, whereas class Iβ is involved in the regulation of platelet degranulation and secretion. The PI3K pathway is a critical signaling pathway in platelet aggregation and activation.

**2.4.1. Influence of the Signal Transduction in Platelet**

It is now thought that many cardiovascular diseases such as atherosclerosis, thrombosis, coronary spasm, acute myocardial infarction, and hypertension have close relationship with platelet aggregation and activation. Upon agonist stimulation, specific receptor of membrane binds to the ligand to make the conformational changes and to activate the key enzymes action, which produces or releases the signal molecules and led to adhesion, aggregation, and reaction release to form thrombus at last. The mechanism of transmembrane signal transduction in platelet is unclear owing to more than one receptor bound by platelet agonist and the activated platelet release α-granules as secondary agonist to bring about amplification effect [69]. Platelet signal transduction pathway usually includes several aspects [70]: PI3-K pathway, PLC-β pathway, PTK pathway, MARK pathway, cAMP-PKA pathway, and PLA2 pathway. At present, most researches are about Phosphoinositide 3-kinase (PI3K). PI3K is a critical transmitter of intracellular signaling during platelet activation. The PI3K family is divided into three classes (I, II, and III). Depending on differences in the heterodimerization of catalytic subunits and regulatory subunits, class I is further divided into class Iα and class Iβ. Class Iα is involved in the regulation of platelet aggregation and activation, whereas class Iβ is involved in the regulation of platelet degranulation and secretion. The PI3K pathway is a critical signaling pathway in platelet aggregation and activation.
divided into IA (PI3Kα, PI3Kβ, and PI3Kγ) and IB (PI3Kδ), PI3Kβ and PI3Kγ are crucial in platelet signaling [71]. Akt phosphorylation can be used as an indicator of PI3K pathway activation [72, 73].

In recent years, with the further study of antiplatelet mechanism of Chinese herb and formulas for PBCRBS, there are studies involving signal transduction in platelet to investigate the mechanism. Salvianolic acid A (SAA, Figure 3) is a water-soluble component from the root of Salvia miltiorrhiza Bunge, a herb that is widely used for atherothrombotic disease treatment in China. New study [74] shows that SAA could inhibit platelet spreading on fibrinogen, a process mediated by outside-in signaling. Western blot analysis showed that SAA, like the PI3K inhibitors LY294002 and TGX-221, potently inhibited PI3K, as shown by reduced akt phosphorylation, which indicates that the target spot may be the PI3Kβ. The in vitro findings were further evaluated in the mouse model of arterial thrombosis, in which SAA prolonged the mesenteric arterial occlusion time in wild-type mice. Interestingly, SAA could even counteract the shortened arterial occlusion time in Ldlr<sup>−/−</sup> mutant mice. And for the first defined the fact [74] that SAA inhibits platelet activation via the inhibition of PI3K and attenuates arterial thrombus formation in vivo. The results suggest that SAA may be developed as a novel therapeutic agent for the prevention of thrombotic disorders.

3. Discussion and Perspective

From above mentioned, during the past 30 years, research of antiplatelet and antithrombotic therapy of Chinese herb and formulas for PBCRBS has made rapid progress, but there are still some problems existing. In the clinical research, at present many studies limited to small sample of curative effects, lack of multicenter, prospective, large sample, and control study which made the clinical practice of Chinese herb and formulas for PBCRBS be short of definite clinical evidence. And Chinese scholars has begun to attempt to study like above and got to some good results [75]. But those which deserve attention are, in the practical use of clinical medicine, we should comply with the principle of differentiation of symptoms and signs, minimize the potential abuse, and improve on the clinical practical effects. In the experimental research, many studies mainly focused on the mechanism on one aspect of a certain Chinese herb and formulas for PBCRBS, the experimental design owes rigor, and only a few studies were equipped with in vitro and in vivo at the same design. It is generally known that platelet activation is a complex, multifactor process, which involves adhesion, aggregation, and reaction release, for example, there are different platelet activation stimulators, which have the different mechanism of platelet aggregation and signal transduction, it is necessary to take a systematic study on the mechanism of Chinese herb and formulas for PBCRBS inhibiting platelet aggregation by different stimulators in the future and making further study on the signal transduction in platelet, now Chinese scholars [74] have made good study and publish the paper on the well-famous journal.

Proteomics technology has been successfully applied to platelet research, contributing to the emerging field of platelet proteomics which led to the identification of a considerable amount of novel platelet proteins, many of which have been further studied at functional level [76]. During the last 3 years, a rapid development of two-dimensional gel electrophoresis and mass spectrometry-based proteomic approaches has been used to profile alterations in platelet proteins [77–79]. Using differential proteomics of platelet, our previous studies found many different platelet proteins [37, 80] between CHD patients of blood stasis syndrome (BSS) and non-BSS patients, and healthy controls, which indicate that the platelet cytoskeleton may play an important role in the development in BSS of CHD. Based on
the Chinese medicine principle of “prescription and syndrome are corresponding”; these platelet differential proteins may be the new target spots or target group. Getting intensive study on it, we believe that we can develop many new antiplatelet and antithrombotic drugs possess definite curative effect and target, clear mechanism.

**Acknowledgment**

This work was supported by the grants from the National Natural Science Foundation of China (Grant no. 81073086 and no. 30901949).

**References**

[1] Antiplatelet Trialists’ Collaboration, “Collaborative overview of randomised trials of antiplatelet therapy—1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients,” *British Medical Journal*, vol. 308, no. 6921, pp. 81–106, 1994.

[2] Antiplatelet Trialists’ Collaboration, “Collaborate meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients,” *British Medical Journal*, vol. 324, no. 7329, pp. 71–86, 2002.

[3] M. Raifferty, M. R. Walters, and J. Dawson, “Anti-platelet therapy and aspirin resistance - Clinically and chemically relevant?” *Current Medicinal Chemistry*, vol. 17, no. 36, pp. 4578–4586, 2010.

[4] A. Pena, J. P. Collet, J. S. Hulot et al., “Can we override clopidogrel resistance?” *Circulation*, vol. 119, no. 21, pp. 2854–2857, 2009.

[5] D. A. Gorog, J. M. Sweeney, and V. Fuster, “Antiplatelet drug ‘resistance’. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact?” *Nature Reviews. Cardiology*, vol. 6, no. 5, pp. 365–373, 2009.

[6] D. N. Juurlink, T. Gomes, D. T. Ko et al., “A population-based study of the drug interaction between proton pump inhibitors and clopidogrel,” *Canadian Medical Association Journal*, vol. 180, no. 7, pp. 713–718, 2009.

[7] J. L. Mega, S. L. Close, S. D. Wiviott et al., “Cytochrome P-450 polymorphisms and response to clopidogrel,” *New England Journal of Medicine*, vol. 360, no. 4, pp. 354–362, 2009.

[8] J. Choi and J. C. Kermode, “New therapeutic approaches to combat arterial thrombosis: better drugs for old targets, novel targets, and future prospects,” *Molecular Interventions*, vol. 11, no. 27, pp. 111–123, 2011.

[9] K. J. Chen, L. D. Li, W. L. Weng et al., “Blood stasis and research of activating blood circulation and eliminating stasis,” *Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi*, vol. 3, no. 1, pp. 1–2, 2005.

[10] K. J. Chen, “Exploration on the possibility of reducing cardiovascular risk by treatment with Chinese medicine recipes for promoting blood-circulation and relieving blood-stasis,” *Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi*, vol. 28, no. 5, p. 389, 2008.

[11] K. J. Chen, M. Xue, and H. J. Yin, “The relationship between platelet activation related factors and polymorphism of related genes in patients with coronary heart disease of blood-stasis syndrome,” *Shoudu Yi Ke Da Xue Xue Bao*, vol. 29, no. 3, pp. 266–269, 2008.

[12] M. Xue, K. J. Chen, and H. J. Yin, “Relationship between platelet activation related factors and polymorphism of related genes in patients with coronary heart disease of blood-stasis syndrome,” *Chinese Journal of Integrative Medicine*, vol. 14, no. 4, pp. 267–273, 2008.

[13] Z. Wang, “Mechanism on modulating platelet function of activating blood circulation and removing stasis herbs,” *Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi*, vol. 12, no. 9, pp. 567–570, 1992.

[14] Society of Cardiology and Chinese Association of the Integration of Traditional and Western Medicine, “The diagnostic criteria of TCM in coronary heart disease,” *Chinese Journal of Integrated Traditional and Western Medicine*, vol. 11, no. 5, p. 257, 1991.

[15] C. G. Fu, *The study of diagnostic criterion on blood stasis for patients with coronary heart disease*, Doctor Dissertation, Beijing University of Chinese Medicine, Beijing, China, 2011.

[16] J. Z. Li, S. L. He, and H. L. Wang, *Thrombosis Epidemiology*, Science Press, Beijing, China, 1998.

[17] F. Q. Xu, K. Y. Chen, X. C. Ma et al., “Clinical observation on effect of xiongshao capsule on coronary heart disease with angina pectoris,” *Zhongguo Zhong Yi Xi Jie He Za Zhi*, vol. 23, no. 1, pp. 16–18, 2003.

[18] J. Feng and S. L. Wang, “Effect of Fufang Danshen Diwan to Platelet Aggregation Function,” *Chinese Journal of Misdiagnostics*, vol. 6, no. 12, pp. 2261–2263, 2006.

[19] J. B. Jiang, J. Yang, and C. Q. Deng, “Effect of Buyang huanwu decoction and its active fraction alkaloid and glycoside on platelet aggregation and cyclic nucleotide in rats,” *Zhong Nan Yao Xue*, vol. 6, no. 4, pp. 388–391, 2008.

[20] J. Wang, J. Xu, and J. B. Zhong, “Effect of Radix notoginseng saponins on platelet activating molecule expression and aggregation in patients with blood hyperviscosity syndrome,” *Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi*, vol. 24, no. 4, pp. 312–316, 2004.

[21] D. S. Wang, F. P. Chen, S. L. He et al., “Mechanism study on Dahuangzhechong pill anti-platelet activation,” *Zhonghua Zhong Yi Yao Za Zhi*, vol. 23, no. 9, pp. 818–821, 2008.

[22] F. Liu, J. Li, and X. D. Wang, “Effect of tongxinluo capsule on platelet aggregation in patients with cerebral infarction,” *Zhongguo Zhong Xi Yi Jie He Za Zhi*, vol. 28, no. 4, pp. 304–306, 2008.

[23] J. M. Li, Y. H. Zhao, G. C. Zhong et al., “Synthesis of ferulic acid derivatives and their inhibitory effect on platelet aggregation,” *Yao Xue Xue Bao*, vol. 46, no. 3, pp. 305–310, 2011.

[24] B. Shu, C. J. Zhou, Y. H. Ma, Y. J. Wang, and Q. Shi, “Research progress on pharmacological activities of the available compositions in Chinese medicinal herb Ligusticum chuanxiong,” *Chinese Pharmaceutical Bulletin*, vol. 22, no. 9, pp. 1043–1047, 2006.

[25] Y. R. Jiang, H. J. Yin, and L. Z. Li, “Treatment of non-ST-elevation acute coronary syndrome with propyl gallate,” *Zhongguo Zhong Xi Yi Jie He Za Zhi*, vol. 28, no. 9, pp. 839–842, 2008.

[26] P. Chen, L. C. Yang, W. Y. Lei, and Z. Q. Shen, “Effects of polydatin on platelet aggregation and platelet cytosolic calcium,” *Tianrun Chan Wu Yan Jiu Yu Kui Fu*, vol. 17, no. 1, pp. 21–25, 2005.

[27] Q. Xia, T. X. Dong, H. Q. Zhan et al., “Inhibition effect of curdione on platelet aggregation induced by ADP in rabbits,” *Chinese Pharmaceutical Bulletin*, vol. 22, no. 9, pp. 1151–1152, 2006.

[28] J. J. Ma, Y. Song, M. Jia, and C. L. Li, “Effect of total flavone in sanguis draconis on platelet aggregation, thrombus formation
Evidence-Based Complementary and Alternative Medicine

and myocardial ischemia,” Zhong Cao Yao, vol. 33, no. 11, pp. 1008–1010, 2002.

[29] Y. Yao, W. Y. Wu, A. H. Liu et al., “Interaction of salvinianolic acids and notoginsenosides in inhibition of ADP-induced platelet aggregation,” American Journal of Chinese Medicine, vol. 36, no. 2, pp. 313–328, 2008.

[30] Z. W. Jiang, L. J. Zhao, H. Zhang et al., “Effect of hirudin injection on antithrombosis in rats,” Ji Lin Da Xue Xue Bao (Yi Xue Ban), vol. 29, no. 4, pp. 417–418, 2003.

[31] Z. Q. Guo, Z. Chen, L. Li et al., “Effect of administration of Safflower yellow injection on the platelet aggregate rate and transforming growth factor-β1 in patients without ST elevation acute myocardial infarction,” Journal of Clinical Cardiology, vol. 26, no. 8, pp. 591–593, 2010.

[32] S. C. Hsu-Lin, C. L. Berman, and B. C. Furie, “A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets,” Journal of Biological Chemistry, vol. 259, no. 14, pp. 19121–19126, 1984.

[33] A. D. Michelson and M. I. Furman, “Laboratory markers of platelet activation and their clinical significance,” Current Opinion in Hematology, vol. 6, no. 5, pp. 342–348, 1999.

[34] H. Ikeda, Y. Takajo, K. Ichiki et al., “Increased soluble form of P-selectin in patients with unstable angina,” Circulation, vol. 92, no. 7, pp. 1693–1696, 1995.

[35] H. Shimomura, H. Ogawa, H. Arai et al., “Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction,” American Journal of Cardiology, vol. 81, no. 4, pp. 397–400, 1998.

[36] M. I. Furman, S. E. Benoit, M. R. Barnard et al., “Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease,” Journal of the American College of Cardiology, vol. 31, no. 2, pp. 352–358, 1998.

[37] Y. Liu, H. J. Yin, Y. R. Jiang et al., “Research on the correlation between platelet gelsoin and blood-stasis syndrome of coronary heart disease,” Chinese Journal of Integrative Medicine, vol. 17, no. 8, pp. 587–592, 2011.

[38] Z. Q. Chen, L. Hong, and H. Wang, “Effect of danhong injection on platelet activation and inflammatory factors in patients of acute coronary syndrome after intervention therapy,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 29, no. 8, pp. 692–694, 2009.

[39] Z. Q. Chen, L. Hong, and H. Wang, “Effect of tetramethylpyrazine on platelet activation and vascular endothelial function in patients with acute coronary syndrome undergoing percutaneous coronary intervention,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 27, no. 12, pp. 1078–1081, 2007.

[40] P. Xiong and L. Zhou, “Effect of compound danshen droplet pill on plasma endothelin and platelet α-granuleMembrane protein-140 in patients with unstable angina pectoris,” Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi, vol. 7, no. 5, pp. 510–511, 2009.

[41] L. Han, D. Y. Peng, F. Xu et al., “Studies on anti-platelet activation effect and partial mechanisms of Taohong Siwu decoction,” Zhongguo Zhong Yao Za Zhi, vol. 35, no. 19, pp. 2609–2612, 2010.

[42] H. M. Luo, D. Y. Fu, M. Z. Ren et al., “Clinical study on tongxinluo capsule affecting activity of platelet’s GP Ib/IIIa receptor in patients with coronary heart disease,” Zhong Cheng Yao, vol. 27, no. 2, pp. 181–183, 2007.

[43] A. Kasirer-Friede, M. R. Cozzi, M. Mazzucato, L. de Marco, Z. M. Ruggeri, and S. J. Shattil, “Signaling through GPIb-IX-V activates αIIbβ3 independently of other receptors,” Blood, vol. 103, no. 9, pp. 3403–3411, 2004.

[44] D. S. Wang, F. P. Chen, S. L. He et al., “Comparative research between plasma pharmacology and serum pharmacology of dahuang zhe chong pill,” Xue Shuan Yu Zhi Xue Xue, vol. 11, no. 1, pp. 5–8, 2005.

[45] Y. L. Li, “Research progress in the treatment of cardiovascular diseases by Xue Fu Zhi Yu Tang,” Beijing Zhong Yi Yao, vol. 27, no. 3, pp. 228–230, 2008.

[46] D. Yaou, J. F. Théorêt, L. Villeneuve et al., “Essential role of protein kinase Cδ in platelet signaling, αIIbβ3 activation, and thromboxane A2 release,” Journal of Biological Chemistry, vol. 281, no. 40, pp. 30024–30035, 2006.

[47] Y. Nishizuka, “Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C,” Science, vol. 258, no. 5082, pp. 607–614, 1992.

[48] Y. M. Yang, X. X. Wang, J. Z. Chen, S. J. Wang, H. Hu, and H. Q. Wang, “Resveratrol attenuates adenosine diphosphate-induced platelet activation by reducing protein kinase C activity,” American Journal of Chinese Medicine, vol. 36, no. 3, pp. 603–613, 2008.

[49] K. L. Kaplan and J. Owen, “Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo,” Blood, vol. 57, no. 2, pp. 199–202, 1981.

[50] C. W. Pumphrey and J. Dawes, “ Plasma beta-thromboglobulin as a measure of platelet activity. Effect of risk factors and findings in ischemic heart disease and after acute myocardial infarction,” American Journal of Cardiology, vol. 50, no. 6, pp. 1258–1261, 1982.

[51] A. Slungaard, “Platelet factor 4: a chemokinetic enigma,” International Journal of Biochemistry and Cell Biology, vol. 37, no. 6, pp. 1162–1167, 2005.

[52] W. Hope, T. J. Martin, C. N. Chesterman, and F. J. Morgan, “Human β-thromboglobulin inhibits PGII production and binds to a specific site in bovine aortic endothelial cells,” Nature, vol. 282, no. 5735, pp. 210–212, 1979.

[53] Y. Q. Kong, Z. Yao, M. L. Yun et al., “Effect of danshen on angina pectoris and platelet function,” Gao Xue Ya Za Zhi, vol. 10, no. 5, pp. 451–453, 2002.

[54] M. Yoshimura, T. Oshima, H. Hiraga et al., “Increased cytosolic free Mg2+ and Ca2+ in platelets of patients with vasospastic angina,” American Journal of Physiology, vol. 274, no. 2, pp. R548–R554, 1998.

[55] A. Fujinishi, K. Takahara, C. Ohba, Y. Nakashima, and A. Kuroiwa, “Effects of niosodpine on cytosolic calcium, platelet aggregation, and coagulation/fibrinolysis in patients with coronary artery disease,” Arteriology, vol. 48, no. 6, pp. 515–521, 1997.

[56] R. X. Zhang, X. F. Lian, and N. Lian, “study progress of calcium antagonist of Chinese medicine on cardiovascular diseases,” Shanxi Zhong Yi Xue Yuan Xue Bao, vol. 22, no. 4, pp. 52–54, 1999.

[57] W. M. Chen, M. Jin, and W. Wu, “study of Safflor yellow inhibit the PAF-induced platelet activation,” Zhongguo Yao Xue Za Zhi, vol. 35, no. 11, pp. 741, 2000.

[58] C. Chen and T. L. Yang, “TXA2/PGI2 and cardiovascular diseases,” Xian Dai Sheng Wu Yi Xue Jin Zhan, vol. 8, no. 11, pp. 2166–2172, 2008.

[59] H. M. Xu, Q. Y. Liu, M. Dai et al., “Effect of total glucosides of radix paeoniae rubra on platelet function of rats,” Heji Gong Ye Da Xue Xue Bao (Zi Ran Ke Xue Ban), vol. 26, no. 1, pp. 141–144, 2003.

[60] H. L. Gao, Y. K. Li, Y. Tong, and L. D. Li, “Comparative study on the protective effects of different Guanxin II formula on
acute myocardial ischemia in dogs," Zhong Yao Yao Li Yu Lin Chuang, vol. 23, no. 5, pp. 1–4, 2007.

[61] Z. X. Lan, W. Z. Wang, Y. N. Ma et al., “Experimental research on the influence of Taohong Siwu decoction on the TXB2,6-keto-PGF1α in the blood stasis syndrom of rats,” Hua Xi Yao Xue Za Zhi, vol. 23, no. 6, pp. 687–688, 2008.

[62] Y. Wu, H. B. Guo, T. J. Wang et al., “Comparative study on effects of active ingredients of several traditional Chinese medicines on rabbit platelet aggregation in vitro,” Zhong Yao Lin Chuang Yao Li Xue Za Zhi, vol. 12, no. 9, pp. 1047–1051, 2007.

[63] W. G. Yu and L. N. Xu, “Effects of acetylsalvianolic acid A on arachidonic acid metabolism in platelets,” Yao Xue Xue Bao, vol. 33, no. 1, pp. 62–63, 1998.

[64] S. J. Yuan, Z. W. Zhang, Gao T. H., and J. H. Pu, “Mechanism research of Honghua injection antithrombotic function,” Zhongguo Zhong Yao Za Zhi, vol. 36, no. 11, pp. 1528–1529, 2011.

[65] Z. Y. Wang, J. Z. Li, and C. G. Ruan, Basic Theory and Clinical of Thrombosis and Hemostasis, Shanghai Scientific and Technical Publishers, Shanghai, China, 2004.

[66] S. H. Xu, “Cyclic nucleotides and blood platelet function,” Sheng Li Ke Xue Jin Zhan, vol. 23, no. 4, pp. 318–322, 1992.

[67] G.G. Zhu, R. Z. Luo, and Z. X. Guo, “Advance of cardiotonic pill on inhibiting platelet activation and aggregation,” Zhongguo Xin Xue Guan Za Zhi, vol. 12, no. 2, pp. 149–151, 2007.

[68] J. Yan and C. L. Qin, “Brief review on effects of Fufangdanshen prescription, Dan-shen and San-qi on the platelet functions,” Zhongguo Shi Yan Fangji Xue Za Zhi, vol. 9, no. 2, pp. 59–62, 2003.

[69] H. Y. Pei and Y. Han, “Platelet activation through signal transduction–review,” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 12, no. 5, pp. 704–707, 2004.

[70] J. Lu, Y. N. Yu, and R. B. Xu, Receptor Signaling System and Diseases, Shandong Science and Technology Press, Shandong, China, 1999.

[71] J. M. E. M. Cosemans, I. C. A. Munnix, R. Wetzker, R. Heller, S. P. Jackson, and J. W. M. Heemskerk, “Continuous signaling via PI3K isoforms β and γ is required for platelet ADP receptor function in dynamic thrombus stabilization,” Blood, vol. 108, no. 9, pp. 3045–3052, 2006.

[72] Z. Li, G. Zhang, G. C. Le Breton, X. Gao, A. B. Malik, and X. Du, “Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases,” Journal of Biological Chemistry, vol. 278, no. 33, pp. 30725–30731, 2003.

[73] C. Kroner, K. Eybrechts, and J. W. N. Akkerman, “Dual regulation of platelet protein kinase B,” Journal of Biological Chemistry, vol. 275, no. 36, pp. 27790–27798, 2000.

[74] Z. S. Huang, C. L. Zeng, L. J. Zhu, L. Jiang, N. Li, and H. Hu, “Salvianolic acid A inhibits platelet activation and arterial thrombosis via inhibition of phosphoinositide 3-kinase,” Journal of Thrombosis and Haemostasis, vol. 8, no. 6, pp. 1383–1393, 2010.

[75] K. J. Chen, D. Z. Shi, H. Xu et al., “XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China,” Chinese Medical Journal, vol. 119, no. 1, pp. 6–13, 2006.

[76] A. Garcia, “Clinical proteomics in platelet research: challenges ahead,” Journal of Thrombosis and Haemostasis, vol. 8, no. 8, pp. 1784–1785, 2010.

[77] T. Thiele, L. Steil, S. Gebhard et al., “Profiling of alterations in platelet proteins during storage of platelet concentrates,” Transfusion, vol. 47, no. 7, pp. 1221–1233, 2007.

[78] C. Banfi, M. Brioschi, G. Marenzi et al., “Proteome of platelets in patients with coronary artery disease," Experimental Hematology, vol. 38, no. 5, pp. 341–350, 2010.

[79] L. Senzel, D. V. Gnatenko, and W. F. Bahou, “The platelet proteome,” Current Opinion in Hematology, vol. 16, no. 5, pp. 329–333, 2009.

[80] X. F. Li, Y. R. Jiang, C. F. Wu, K. J. Chen, and H. J. Yin, “Study on the correlation between platelet function proteins and symptom complex in coronary heart disease,” Zhongguo Fen Zi Xin Zang Bing Xue Za Zhi, vol. 9, no. 6, p. 326, 2009.